Cormorant Asset Management LP 13D and 13G filings for Constellation Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 3:01 pm Sale | 2023-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST | Cormorant Asset Management LP | 0 0.000% | -5,150,000 (Position Closed) | Filing |
| 2023-02-14 3:14 pm Sale | 2022-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST | Cormorant Asset Management LP | 5,150,000 9.210% | -290,451 (-5.34%) | Filing |
| 2022-02-14 3:08 pm Purchase | 2021-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST | Cormorant Asset Management LP | 5,440,451 9.770% | 325,607 (+6.37%) | Filing |
| 2021-04-09 4:07 pm Purchase | 2021-03-30 | 13G | Constellation Pharmaceuticals, Inc. CNST | Cormorant Asset Management LP | 5,114,844 9.200% | 5,114,844 (New Position) | Filing |
| 2021-02-16 3:11 pm Sale | 2020-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST | Cormorant Asset Management LP | 0 0.000% | -2,300,000 (Position Closed) | Filing |